Agreement technologies and their use in cloud computing environments

The final publication is available at Springer via http://dx.doi.org/10.1007/s13748-012-0031-9[EN] Nowadays, cloud computing is revolutionizing the services provided through the Internet to adapt itself in order to keep the quality of its services. Recent research foresees the advent of a new discipline of agent-based cloud computing systems that can make decisions about adaption in an uncertain environment. This paper discusses the role of argumentation in the next generation of agreement technologies and its use in cloud computing environments.This work is supported by the Spanish government (MICINN), project reference: TIN2012-36586-C03-01.Heras Barberá, SM.; De La Piedra, F.; Julian Inglada, VJ.; Rodríguez, S.; Botti Navarro, VJ.; Bajo, J.; Corchado, JM. (2012). Agreement technologies and their use in cloud computing environments. Progress in Artificial Intelligence. 1(4):277-290. https://doi.org/10.1007/s13748-012-0031-9S27729014European Comission: The Future of Cloud Computing. Technical report (2010)Barham, P., Dragovic, B., Fraser, K., Hand, S., Harris, T., Ho, A., Neugebauer, R., Pratt, I., Warfield, A.: Xen and the art of virtualization. In: SOSP03 Proceedings of the Nineteenth ACM Symposium on Operating Systems Principles, pp. 164–177. ACM, New York (2003)Wang, L., et. al.: Scientific cloud computing: early definition and experience. In: 10th IEEE International Conference on High Performance Computing and Communications (HPCC-08), pp. 825–830. IEEE Press (2008)Talia, D.: Clouds meet agents: toward intelligent cloud services. Internet Comput. IEEE 16(2), 78–81 (2012). doi: 10.1109/MIC.2012.28Heras, S.: Case-Based Argumentation Framework for Agent Societies. PhD thesis, Universitat Politècnica de València. http://hdl.handle.net/10251/12497 (2011)Ashton, K.: That ‘internet of things’ thing. RFID J. (2009). http://www.rfidjournal.com/article/view/4986Klusch, M.: Information agent technology for the Internet: a Survey. Data Knowl. Eng. 36, 337–372 (2001)Schaffer, H.E.: X as a Service. Cloud Computing, and the Need for Good Judgment IT Professional 11(5), 4–5 (2009). doi: 10.1109/MITP.2009.112Richardson, L., Ruby, S.: RESTful Web Services, Web services for the real world O’Reilly, Media, May, p. 454 (2007)GlusterFS Developers. The Gluster web site. http://www.gluster.org (2012)Chodorow, K., Dirolf, M.: The Definitive Guide. O’Reilly Media, MongoDB (2010)Fuentes-Fernandez, R., Hassan, S., Pavon, J., Galan, J.M., Lopez-Paredes, A.: Metamodels for role-driven agent-based modelling. Comput. Math. Organ. Theory 18(1), 91–112 (2012)Jordán, J., et al.: A customer support application using argumentation in multi-agent systems. In: 14th International Conference on, Information Fusion, pp. 772–778 (2011)Heras, S., Jordán, J., Botti, V., Julián, V.: Argue to agree: a case-based argumentation approach. Int. J. Approx. Reasoning (2012, in press)Walton, D., Reed, C., Macagno, F.: Argumentation Schemes. Cambridge University Press, Cambridge (2008)Bench-Capon, T., Sartor, G.: A model of legal reasoning with cases incorporating theories and values. Artif. Intell. 150(1–2), 97–143 (2003)Dignum, F., Weigand, H.: Communication and deontic logic. In: Information Systems Correctness and Reusability, pp. 242–260. World Scientific, Singapore (1995)Wooldridge, M., Jennings, N.R.: Intelligent agents: theory and practice. Knowl. Eng. Rev. 10(2), 115–152 (1995)Lopez-Rodriguez, I., Hernandez-Tejera, M.: Software agents as cloud computing services. In: 9th International Conference on Practical Applications of Agents and Multiagent Systems. Advances in Intelligent and Soft Computing, vol. 88, pp. 271–276. Springer, Berlin (2011)Sim, K.M.: Towards complex negotiation for cloud economy. In: 5th International Conference on Advances in Grid and Pervasive Computing. LNCS, vol. 6104, pp. 395–406. Springer, Berlin (2010)Aversa, R., et al.: Cloud agency: a mobile agent based cloud system. In: International Conference on Complex, Intelligent and Software Intensive Systems, pp. 132–137. IEEE Computer Society Press, Washington, DC (2010)Cao, B., et al.: A service-oriented qos-assured and multi-agent cloud computing architecture. In: 1st International Conference on Cloud Computing. LNCS, vol. 5931, pp. 644–649. Springer, Berlin (2009)Rahwan, I., Simari, G. (eds.): Argumentation in Artificial Intelligence. Springer, Berlin (2009

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study

Background: Levels of bone turnover markers (BTM) might be correlated with outcome in terms of skeletal-related events (SRE), disease progression, and death in patients with bladder cancer (BC) and renal cell carcinoma (RCC) with bone metastases (BM). We try to evaluate this possible correlation in patients who receive treatment with zoledronic acid (ZOL). Methods: This observational, prospective, and multicenter study analysed BTM and clinical outcome in these patients. Serum levels of bone alkaline phosphatase (BALP), procollagen type I amino-terminal propeptide (PINP), and beta-isomer of carboxyterminal telopeptide of type I collagen (b-CTX) were analysed. Results: Patients with RCC who died or progressed had higher baseline b-CTX levels and those who experienced SRE during follow-up showed high baseline BALP levels. In BC, a poor rate of survival was related with high baseline b-CTX and BALP levels, and new SRE with increased PINP levels. Cox univariate analysis showed that b-CTX levels were associated with higher mortality and disease progression in RCC and higher mortality in BC. Bone alkaline phosphatase was associated with increased risk of premature SRE appearance in RCC and death in BC. Conclusion: Beta-isomer of carboxy-terminal telopeptide of type I collagen and BALP can be considered a complementary tool for prediction of clinical outcomes in patients with BC and RCC with BM treated with ZOLNovartis Oncology Spain for supporting this stud

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

Owing to the limited validity of clinical data on the treatment of prostate cancer (PCa) and bone metastases, biochemical markers are a promising tool for predicting survival, disease progression and skeletal-related events (SREs) in these patients. The aim of this study was to evaluate the predictive capacity of biochemical markers of bone turnover for mortality risk, disease progression and SREs in patients with PCa and bone metastases undergoing treatment with zoledronic acid (ZA). Methods: This was an observational, prospective and multicenter study in which ninety-eight patients were included. Patients were treated with ZA (4mg every 4 weeks for 18 months). Data were collected at baseline and 3, 6, 9, 12, 15 and 18 months after the beginning of treatment. Serum levels of bone alkaline phosphtase (BALP), aminoterminal propeptide of procollagen type I (P1NP) and beta-isomer of carboxiterminal telopeptide of collagen I (b-CTX) were analysed at all points in the study. Data on disease progression, SREs development and survival were recorded. Results: Cox regression models with clinical data and bone markers showed that the levels of the three markers studied were predictive of survival time, with b-CTX being especially powerful, in which a lack of normalisation in visit 1 (3 months after the beginning of treatment) showed a 6.3-times more risk for death than in normalised patients. Levels of these markers were also predictive for SREs, although in this case BALP and P1NP proved to be better predictors. We did not find any relationship between bone markers and disease progression. Conclusion: In patients with PCa and bone metastases treated with ZA, b-CTX and P1NP can be considered suitable predictors for mortality risk, while BALP and P1NP are appropriate for SREs. The levels of these biomarkers 3 months after the beginning of treatment are especially importantThis study was supported by Novartis Oncology Spai

Hard color-singlet exchange in dijet events in proton-proton collisions at root s=13 TeV

Events where the two leading jets are separated by a pseudorapidity interval devoid of particle activity, known as jet-gap-jet events, are studied in proton-proton collisions at root s = 13 TeV. The signature is expected from hard color-singlet exchange. Each of the highest transverse momentum (p(T)) jets must have p(T)(jet) > 40 GeV and pseudorapidity 1.4 0.2 GeV in the interval vertical bar eta vertical bar < 1 between the jets are observed in excess of calculations that assume only color-exchange. The fraction of events produced via color-singlet exchange, f(CSE), is measured as a function of p(T)(jet2), the pseudorapidity difference between the two leading jets, and the azimuthal angular separation between the two leading jets. The fraction f(CSE) has values of 0.4-1.0%. The results are compared with previous measurements and with predictions from perturbative quantum chromodynamics. In addition, the first study of jet-gap-jet events detected in association with an intact proton using a subsample of events with an integrated luminosity of 0.40 pb(-1) is presented. The intact protons are detected with the Roman pot detectors of the TOTEM experiment. The f(CSE) in this sample is 2.91 +/- 0.70(stat)(-1.01)(+1.08)(syst) times larger than that for inclusive dijet production in dijets with similar kinematics.Peer reviewe

Gestión del conocimiento. Perspectiva multidisciplinaria. Volumen 17

El libro “Gestión del Conocimiento. Perspectiva Multidisciplinaria”, Volumen 17 de la Colección Unión Global, es resultado de investigaciones. Los capítulos del libro, son resultados de investigaciones desarrolladas por sus autores. El libro es una publicación internacional, seriada, continua, arbitrada, de acceso abierto a todas las áreas del conocimiento, orientada a contribuir con procesos de gestión del conocimiento científico, tecnológico y humanístico. Con esta colección, se aspira contribuir con el cultivo, la comprensión, la recopilación y la apropiación social del conocimiento en cuanto a patrimonio intangible de la humanidad, con el propósito de hacer aportes con la transformación de las relaciones socioculturales que sustentan la construcción social de los saberes y su reconocimiento como bien público

Study of exclusive two-photon production of W+W- in pp collisions at √s=7 TeV and constraints on anomalous quartic gauge couplings

A search for exclusive or quasi-exclusive W+W- production by photon-photon interactions, pp -> p(*)W(+)W(-)p(*), at \/s = 7 TeV is reported using data collected by the CMS detector with an integrated luminosity of 5.05 fb(-1). Events are selected by requiring a mu(+/-)mu(-/+) vertex with no additional associated charged tracks and dilepton transverse momentum p(T)(mu(+/-)mu(-/+)) > 30 GeV. Two events passing all selection requirements are observed in the data, compared to a standard model expectation of 2.2 +/- 0.4 signal events with 0.84 +/- 0.15 background. The tail of the dilepton p(T) distribution is studied for deviations from the standard model. No events are observed with p(T) > 100 GeV. Model-independent upper limits are computed and compared to predictions involving anomalous quartic gauge couplings. The limits on the parameters a(0,c)(W)/A(2) with a dipole form factor and an energy cutoff A(cutoff) = 500 GeV are of the order of 10(-4)

The Usefulness of Bone Biomarkers for Monitoring Treatment Disease: A Comparative Study in Osteolytic and Osteosclerotic Bone Metastasis Models

BACKGROUND: The skeleton is the most common site of colonization by metastatic cancers. Zoledronic acid (ZA) has been shown to be effective for the treatment of bone metastases regardless of whether the bone lesions are osteolytic or osteoblastic. Biochemical markers of bone turnover may be useful tools to quantify the degree of bone remodeling in the presence of bone metastases. The aim of this work was to establish the correlation between tumor dispersion (bioluminescence) and biochemical markers of bone turnover in two osteolytic and osteoblastic metastasis models in mice. METHODS: The A549M1 cell line that produces osteolytic metastases and the LADOB cell line extracted from a patient with a lung carcinoma and osteoblastic metastases cells were retrovirally transduced with a luciferase reporter gene for in vivo image analysis. Forty-four-week–old mice were inoculated in the left cardiac ventricle with A549M1 or LADOB cells. Twenty mouse of each group were treated with a single dose of ZA (70 μg/kg) 5 days after i.c. Ten animals of each group were sacrificed at 21 and 28 days postinoculation in A549M1 and 60 and 75 days in the LADOB assay. Bioluminescence analysis was quantified 7, 14, 21 ,and 28 days postinoculation in A549M1 mice and 33, 45, 60, and 75 days after inoculation in LADOB mice. Osteocalcin (BGP), aminoterminal propeptide of procollagen I (PINP), carboxiterminal telopeptide of type I collagen (CTX), and 5b isoenzyme of tartrate-resistant acid phosphatase were measured by ELISA (IDS, UK). RESULTS: Bioluminescence imaging revealed a significant increase of tumor burden on time in both osteolytic and osteoblastic mice models. ZA administration resulted in a significant decrease in tumor burden at 21 and 28 days in the A549M1 animals and 60 and 70 days postinoculation in the LADOB line. Biomarkers levels were significantly increased in the untreated group at every point in the osteolytic model. In the osteoblastic model, 2 months after inoculation, all biomarkers were significantly increased. However, 2.5 months postinoculation, only PINP and CTX were significantly increased. Serum bone remodeling markers decreased in ZA-treated mice as compared with tumor groups in both models. With respect to the correlation between bone turnover markers and tumor burden, in the osteolytic model, PINP and BGP demonstrate a strong correlation with bioluminescence in both tumoral and ZA animals, and only CTX was significantly associated with bioluminescence in the group of animals that were not treated with ZA. CONCLUSIONS: We found that the best biomarkers for the diagnosis of both osteolytic and osteoblastic metastasis are formation markers, especially BGP. Moreover, these markers can be useful in the follow-up of the treatment with ZA in both types of metastasis